Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Charles River Laboratories International, Inc.    CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/27/2020 Date
232.54(c) 232.01(c) 224.68(c) 226.35(c) 230.16(c) Last
288 038 220 668 265 393 188 973 73 048 Volume
-0.39% -0.23% -3.16% +0.74% +1.68% Change
More quotes
Financials (USD)
Sales 2020 2 889 M - -
Net income 2020 296 M - -
Net Debt 2020 1 550 M - -
P/E ratio 2020 39,2x
Yield 2020 -
Sales 2021 3 181 M - -
Net income 2021 358 M - -
Net Debt 2021 1 136 M - -
P/E ratio 2021 32,7x
Yield 2021 -
Capitalization 11 449 M 11 449 M -
EV / Sales 2020 4,50x
EV / Sales 2021 3,96x
Nbr of Employees 17 100
Free-Float 98,2%
More Financials
Company
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in... 
Sector
Biotechnology & Medical Research
Calendar
12/02 | 09:40amPresentation
More about the company
All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
11/12CHARLES RIVER : and PathoQuest Strengthen Strategic Partnership
BU
11/09CHARLES RIVER LABORATORIES INTERNATI : Management's Discussion and Analysis of F..
AQ
11/09CHARLES RIVER LABORATORIES INTERNATI : to Present at Upcoming Investor Conferenc..
BU
10/29CHARLES RIVER LABORATORIES INTERNATI : Management's Discussion and Analysis of F..
AQ
10/29CHARLES RIVER LABORATORIES INTERNATI : Results of Operations and Financial Condi..
AQ
10/29CHARLES RIVER LABORATORIES INTERNATI : Q3 2020 Earnings Presentation
PU
10/29CHARLES RIVER : 3Q Earnings Snapshot
AQ
10/29CHARLES RIVER LABORATORIES : Announces Third-Quarter 2020 Results
BU
10/19CHARLES RIVER LABORATORIES INTERNATI : Change in Directors or Principal Officers..
AQ
10/16CHARLES RIVER LABORATORIES INTERNATI : Adds George Llado to Board of Directors
BU
10/13CHARLES RIVER LABORATORIES INTERNATI : Schedules Third-Quarter 2020 Earnings Rel..
BU
09/08CHARLES RIVER LABORATORIES INTERNATI : to Present at September Investor Conferen..
BU
08/27CHARLES RIVER LABORATORIES INTERNATI : Intra-Industry Collaboration
PU
08/05CHARLES RIVER LABORATORIES INTERNATI : Management's Discussion and Analysis of F..
AQ
08/05CHARLES RIVER LABORATORIES INTERNATI : Results of Operations and Financial Condi..
AQ
More news
News in other languages on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
02/06CHARLES RIVER LABORATORIES INTERNATI : Veröffentlichung des Jahresergebnisses
02/06CHARLES RIVER LABORATORIES INTERNATI : publication des résultats annuels
2017CHARLES RIVER LABORATORIES INTL : annonce la réussite d'un projet de recherche i..
2014CHARLES RIVER LABORATORIES : publication des résultats trimestriels
2013CHARLES RIVER LABORATORIES : publication des résultats trimestriels
More news
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 255,88 $
Last Close Price 230,16 $
Spread / Highest target 23,4%
Spread / Average Target 11,2%
Spread / Lowest Target -32,7%
EPS Revisions
Managers
NameTitle
James C. Foster Chairman, President & Chief Executive Officer
David Ross Smith Chief Financial Officer & Executive Vice President
Shanna L. Cotti-Osmanski Chief Information Officer
George E. Massaro Independent Director
George M. Milne Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.48.17%11 449
LONZA GROUP AG55.15%44 901
MODERNA, INC.549.44%43 204
CELLTRION, INC.82.04%39 811
IQVIA HOLDINGS INC.9.26%32 568
SEAGEN INC.48.01%29 832